Edris Badreddin 4

What Happened

• Edris Badreddin, a director of Edgewise Therapeutics (EWTX), was granted two equity awards on June 5, 2026: 5,619 restricted stock units (RSUs) and 8,188 stock options. Both grants are reported as derivative awards with an acquisition price of $0 in the Form 4 filing.

Key Details

• Transaction date: June 5, 2026 (Form 4 filed June 16, 2026).
• Awards: 5,619 RSUs and 8,188 stock options; acquisition price reported as $0 (grant/award).
• Vesting (footnotes):
  • RSUs: 100% vest on the earlier of June 5, 2027 or the business day prior to the 2027 annual meeting.
  • Stock options: 100% vest on the earlier of June 5, 2027 or the business day prior to the 2027 annual meeting.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Timeliness: The Form 4 was filed 11 days after the transaction date; this is later than the typical two-business-day filing requirement for Form 4s.

Context

• These awards are compensation-style grants to a director (common for board pay) rather than purchases or sales. RSUs convert to common shares upon vesting; options give the holder the right to buy shares under the option terms (exercise price not shown in the provided summary).
• Such grants are routine corporate compensation and do not by themselves indicate a buy/sell decision by the insider.